Pulmonary disease
Study
Human trials assessed pulmonary outcomes; the larger intravenous trial was negative.1
Immune
VIP
Vasoactive intestinal peptide
No FDA-approved product identified for this exact research entry in the targeted review.
What does it do?
Amino-acid sequence
- His
- Ser
- Asp
- Ala
- Val
- Phe
- Thr
- Asp
- Asn
- Tyr
- Thr
- Arg
- Leu
- Arg
- Lys
- Gln
- Met
- Ala
- Val
- Lys
- Lys
- Tyr
- Leu
- Asn
- Ser
- Ile
- Leu
- Asn
28 residues · N → C17
Reference identity · not independently confirmed17
Length28 amino acids
Molecular weight · Da3326.8 Da
His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH2Identity reported by Pep-Pedia; exact-product sequence and modifications have not been independently confirmed.
The exact formulation, clinical benefits and long-term safety require further verification.
Pharmacokinetics
Unverified reference estimateNot independently confirmed
Reference half-life30 min16
Route / formulationSource page: Nasal. Exact PK route not verified.
This value is reported by a secondary reference. The stated attribution has not been independently verified as a route- and formulation-matched human PK measurement.
50%of reference level
Illustrative scenario using an unverified reference estimate.
About 3% remaining after 2.5 h
Five half-lives in this estimated model. This is not a prediction of when effects stop.
About this estimate
Population: Not established by the reference estimate
Source’s stated attribution: Youssef et al. 2022
Source’s reported peak time: 15 min. This has not been independently confirmed and is not used in the elimination curve.
100 × 2−time / half-life. Time zero is a reference level, not the moment of administration. Absorption, repeated dosing, metabolites and clinical effects are not modeled. Five half-lives leaves 3.125%, not zero. This curve cannot determine a dosing interval.
What to expect
Study outcomes
Large intravenous trial was negative
The larger intravenous trial did not demonstrate clinical benefit.1
Route matters
Preliminary inhaled findings cannot be transferred to injected or intranasal formulations.2
Reported timelines
Reference & communitySource expectations
Nasal sleep/energy 1–2 weeks, inflammation 2–8+, months for CIRS; injection claims 2–12 weeks. No validated universal timeline.17
These are reported timelines, not a prediction of your response.
Doses & schedules
Route
Scroll to compare all columns →
| Route | Dose | Frequency | Goal / evidence | Duration | References |
|---|---|---|---|---|---|
| IVIntravenous | 600 pmol/kg | 12-hour infusion | COVID-19 hypoxaemic respiratory failureHospitalized adults in TESICOHuman study | Day 1 | 1 |
Population Hospitalized adults in TESICO Context Negative hospital-based trial; not a community treatment regimen. Source dose wording 600, 1,200 and 1,800 pmol/kg on successive days | |||||
| IVIntravenous | 1200 pmol/kg | 12-hour infusion | COVID-19 hypoxaemic respiratory failureHospitalized adults in TESICOHuman study | Day 2 | 1 |
Population Hospitalized adults in TESICO Context Negative hospital-based trial; not a community treatment regimen. Source dose wording 600, 1,200 and 1,800 pmol/kg on successive days | |||||
| IVIntravenous | 1800 pmol/kg | 12-hour infusion | COVID-19 hypoxaemic respiratory failureHospitalized adults in TESICOHuman study | Day 3 | 1 |
Population Hospitalized adults in TESICO Context Negative hospital-based trial; not a community treatment regimen. Source dose wording 600, 1,200 and 1,800 pmol/kg on successive days | |||||
| IntranasalNasal | 50 mcg per spray, 4-8 sprays/day | 4x daily | CIRS protocol (Shoemaker)Reference report | 4-12 weeks or ongoing based on condition | 17 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Shoemaker screening/lab sequences are protocol claims, not FDA instructions. Source tabs Nasal | |||||
| IntranasalNasal | 50-100 mcg | 2-4x daily | General immune supportReference report | 4-12 weeks or ongoing based on condition | 17 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Shoemaker screening/lab sequences are protocol claims, not FDA instructions. Source tabs Nasal | |||||
| IntranasalNasal | 50 mcgStarting dose | 2x daily | Starting/sensitive patientsReference report | 4-12 weeks or ongoing based on condition | 17 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Shoemaker screening/lab sequences are protocol claims, not FDA instructions. Source tabs Nasal | |||||
| IntranasalNasal | 100-200 mcg | 2-4x daily | Advanced/maintenanceReference report | 4-12 weeks or ongoing based on condition | 17 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Shoemaker screening/lab sequences are protocol claims, not FDA instructions. Source tabs Nasal | |||||
| SubQ | 10-30 mcgStarting dose | 1x daily | Starting / Assess toleranceReference report | 3 months on | 17 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Shoemaker screening/lab sequences are protocol claims, not FDA instructions. Source tabs Injectable | |||||
| SubQ | 200 mcg (0.2 mg) | 5x weekly (Mon-Fri) | Standard protocolReference report | 3 months on | 17 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Shoemaker screening/lab sequences are protocol claims, not FDA instructions. Source tabs Injectable | |||||
| SubQ | 1 mg/week | Split across 5 doses | Weekly totalReference report | 3 months on | 17 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Shoemaker screening/lab sequences are protocol claims, not FDA instructions. Source tabs Injectable | |||||
| SubQSubQ (repeat annually x3 cycles) | 200 mcg | 3 months on, 1 month off | Cycle protocolReference report | 3 months on | 17 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Shoemaker screening/lab sequences are protocol claims, not FDA instructions. Source tabs Injectable | |||||
No protocols match these filters.
Study and label doses retain their study context. Reference reports are unvalidated practices, not personal treatment instructions. Ranges remain ranges; escalation stages are labeled.
Reported use periods and breaks. These do not establish a safe cycle or prove that breaks prevent tolerance.
Nasal
- Use period
- 4-12 weeks or ongoing based on condition
- Break
- May use continuously under medical supervision
Reported timing
Morning and evening, or spread throughout day
Injectable
- Use period
- 3 months on
- Break
- 1 month off, repeat x3 cycles annually
Reported timing
Consistent time daily, earlier in day preferred for circadian alignment
Side effects & safety
Evidence limitation
The day-5 serious safety composite occurred in 63% versus 56%; the difference was not statistically significant.
1Evidence limitation
Results in critically ill patients do not establish safety of self-administered VIP.
1Common
Flushing, headache, nausea, diarrhea, nasal irritation and hypotension.
Urgent
Abdominal pain/lipase elevation, persistent diarrhea/vomiting, fainting, chest pain/dyspnea, severe headache or allergy.
Context
BP drugs and pregnancy/breastfeeding require caution; trial monitoring is not home-use reassurance.
Not a complete safety screen. Discuss health decisions with a qualified clinician.
Combinations & interactions
9 entriesCheck cautions and reported pairings. A compatibility claim does not establish that a combination is safe.
BPC-157
Unverified pairingUntested pairing.17
Reference report · Pep-Pedia label: CompatibleThymosin Alpha-1
Unverified pairingUntested pairing.17
Reference report · Pep-Pedia label: SynergisticLL-37
Unverified pairingUntested pairing.17
Reference report · Pep-Pedia label: CompatibleKPV
Unverified pairingUntested pairing.17
Reference report · Pep-Pedia label: SynergisticSelank
Unverified pairingUntested pairing.17
Reference report · Pep-Pedia label: CompatibleDSIP
Unverified pairingUntested pairing.17
Reference report · Pep-Pedia label: CompatibleCerebrolysin
Related compoundComposition/mechanistic claim unverified.17
Reference report · Pep-Pedia label: SimilarGHK-Cu
Unverified pairingUntested pairing.17
Reference report · Pep-Pedia label: CompatibleOther pulmonary or vasoactive treatments
Not establishedUse alongside standard care in hospital trials does not validate arbitrary drug combinations or mixing in one vial.12
Research contextNo matching interactions. Try another name or filter.
Reconstitution
Clinical trials used controlled investigational formulations; no universal research-vial preparation was verified.12
Reference preparation details
Reported handling information, not a validated formulation or instruction to prepare an injectable product.
Nasal
The source describes a pharmacy-compounded nasal spray.
- Form
- Source describes a prepared product
- Reported parameters
- Reported storage: 2–8°C; actual metered pump output determines amount per spray.
Injectable
The source gives a 5 mg vial example.
- Solvents mentioned
- Bacteriostatic water
- Reported parameters
- 5 mg in 5 mL gives 1 mg/mL. · At that concentration, 200 mcg occupies 0.2 mL (20 U-100 syringe units). · Reported storage: 2–8°C.
The source describes gentle mixing and avoiding vigorous shaking.
Appearance & documentation
Appearance and a purity certificate cannot establish sterility, identity, or suitability for injection.
Reported appearanceClear SolutionReported appearanceProper Spray FunctionReported appearanceLicensed Compounding PharmacyReported variationTemperature During ShippingReported concernCloudiness or ParticlesReported concernDiscoloration
17Available forms
No verified packaging examples included.
Packaging examples, not a market survey. Approved and research products are not interchangeable.
Storage after mixing
Reconstituted research vials
Refrigerated lifetime not established
The checked sources do not establish how long this research preparation remains stable and sterile after mixing.17
Storage depends on the formulation, diluent, container, and handling. Follow the specific product label or pharmacist’s instructions.
Evidence limits
View findings →An effect in a small inhaled study would not establish effectiveness of intravenous or community intranasal products.1
3 distinct primary sources or abstracts checked. Evidence may concern a parent compound, individual blend ingredient, animal, or cell model; it does not necessarily establish a benefit for this exact product.
Evidence definitions →Research findings
Human trialsSource context
Shoemaker screening/lab sequences are protocol claims, not FDA instructions.
Compound identity & other names
VIP, including synthetic aviptadil, is investigated in pulmonary and inflammatory conditions. A larger IV COVID-19 trial was negative; a smaller inhaled trial reported faster discharge. Neither establishes intranasal community protocols.
No FDA-approved product identified for this exact research entry in the targeted review.
Vasoactive intestinal peptide317
Pep-Pedia identity record
28 amino acids · 3326.8 Da
His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH2Reference description; checked chemical identity takes precedence when available.17
How it may work
VPAC1/2 signaling increases cAMP and affects vascular tone and immune responses.17
Large intravenous trial was negative
TESICO found no improvement in day-90 outcomes with aviptadil: odds ratio 1.11 (95% CI 0.80–1.55). Mortality was 38% versus 36% with placebo. The trial stopped for futility.
1Smaller inhaled trial has a different result
A 2025 study in 80 patients reported hospitalization averaging 7.8 versus 10 days with inhaled treatment. The small sample and different route limit comparison with the negative intravenous trial.
2Source checks & newer research
TESICO randomized IV aviptadil trial
Aviptadil did not significantly improve recovery or mortality through day 90 in COVID hypoxemic respiratory failure; hypotension, flushing and diarrhea were more common. Findings concern monitored IV therapy, not nasal CIRS use.
Randomized placebo-controlled trial18Research areas and evidence gaps
Pulmonary disease research. Human trials assessed pulmonary outcomes; the larger intravenous trial was negative.1
- An effect in a small inhaled study would not establish effectiveness of intravenous or community intranasal products.
- A product-specific research-vial quantity was not independently verified in this review.
Additional uses listed by Pep-Pedia
Inflammation. CIRS, autoimmune and respiratory claims.17
Neurological. Cognition, neuroprotection, sleep/circadian and mood research.17
Vascular / lung. Pulmonary hypertension, perfusion, cardiac and COVID-ARDS research; results vary.17
Community reports Unvalidated
Pep-Pedia discusses pulmonary and inflammatory research.3
Editorial summary, not a measured community survey, clinical protocol or recommendation.
Search coverage and review status
Added the larger negative intravenous TESICO trial and the smaller 2025 inhaled study. Their populations, routes and findings differ.
- Checked
- 2026-10-12
- Search
- "aviptadil" 2025 2026 trial; TESICO 2023
- Catalog
- Pep-Pedia ↗ · 12 listed references retained
- Targeted search and selected primary-source checks, not an exhaustive systematic review.
- Preserved bibliography entries marked unreviewed have not had their findings independently verified.
AI-prepared summaries. Independent medical editorial review is pending.
Community poll 10 topics · Pep-Pedia snapshot
Voluntary, unverified reports. These percentages do not measure effectiveness or safety.
Experience
The source hides 1 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Duration of use
The source hides 1 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Age range
Number of responses to this question: not disclosed.
Gender
Number of responses to this question: not disclosed.
Primary goal
The source hides 3 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Effectiveness
The source hides 2 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Side effects
The source hides 7 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Dosage frequency
The source hides 1 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Would recommend
Number of responses to this question: not disclosed.
How discovered
Number of responses to this question: not disclosed.
Source & limitations
The source displays “247 responses” for this profile. This is not a confirmed participant count or a denominator for individual questions.
- Voluntary self-reports from Pep-Pedia visitors; identity, treatment, outcomes and timing are unverified. These data are not efficacy or safety estimates.
- The source displays a profile-wide response label, not a confirmed unique participant count. It stays unchanged across questions. Question-specific denominators and absolute option counts are not exposed.
- Only the top five categories are displayed for some questions. Extra categories are retained as an undisplayed-category count; their labels and percentages are unavailable.
- Displayed percentages are rounded. They may not total 100%, especially where categories are hidden.
- This is a dated snapshot, not a live survey or current recommendation.
References
Original sources and review status. Open a reference to read its summary.
1Intravenous aviptadil and remdesivir for COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trialAbstract checked
AI-PREPARED SUMMARY
Among 461 treated participants, aviptadil did not improve the day-90 clinical outcome or survival versus placebo. The trial stopped for futility.
Large intravenous trial was negative
TESICO found no improvement in day-90 outcomes with aviptadil: odds ratio 1.11 (95% CI 0.80–1.55). Mortality was 38% versus 36% with placebo. The trial stopped for futility.
Additional research · Checked 2026-10-12
2Inhaled Aviptadil Is a New Hope for Recovery of Lung Damage due to COVID-19Abstract checked
AI-PREPARED SUMMARY
An 80-patient randomized study reported shorter hospitalization with inhaled aviptadil added to usual care. This small study used a different route from TESICO and does not establish a mortality benefit.
Smaller inhaled trial has a different result
A 2025 study in 80 patients reported hospitalization averaging 7.8 versus 10 days with inhaled treatment. The small sample and different route limit comparison with the negative intravenous trial.
Additional research · Checked 2026-10-12
3Pep-Pedia: VIPCommunity source checked
AI-PREPARED SUMMARY
Secondary editorial profile and reported practices; not clinical validation.
4IV Aviptadil in Critical COVID-19 Respiratory Failure - Phase 2b/3 RCT (2022)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The source reports higher 60-day survival odds in one COVID trial; endpoint hierarchy and later trials must be considered before claiming efficacy.
Reported population / model
Humans
Reported study details
196 patients · IV infusion · 60 days · 2-fold increased survival odds
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
5VIP Corrects Chronic Inflammatory Response Syndrome (2013)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The source attributes broad CIRS improvements to nasal VIP; controlled design and attribution of later imaging/molecular claims need verification.
Reported population / model
Humans
Reported study details
CIRS patients · Nasal spray 50mcg · Multiple months · Correction of inflammatory markers
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
6IUPHAR Review: VIP and PACAP Receptor Pharmacology (2012)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The receptor review details VIP/PACAP signaling and physiology; target mechanisms do not establish clinical efficacy across the discussed diseases.
Reported population / model
Review
Reported study details
Comprehensive analysis of VPAC1/VPAC2/PAC1 receptors
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
7VIP Prevents Experimental Arthritis (2001)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: A mouse arthritis model reportedly showed less joint inflammation and structural damage after VIP exposure.
Reported population / model
Mice
Reported study details
CIA model · IP injection · 2 weeks · Complete prevention of joint destruction
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
8Intranasal VIP Pharmacodynamics and Toxicity (2013)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The source reports brain delivery and better animal memory with limited nasal irritation; it does not establish human intranasal safety.
Reported population / model
Animal model
Reported study details
40-200mcg/mL · 1 week · Safe brain delivery confirmed
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
9Inhaled VIP in Pulmonary Hypertension (2008)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Twenty patients had acute pulmonary vascular changes; six exceeded a 20% resistance reduction after inhalation, without establishing long-term outcomes.
Reported population / model
Humans
Reported study details
20 PH patients · 100mcg inhaled · Acute study · Selective pulmonary vasodilation
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
10Pharmacology and functions of VIP and PACAP receptors: IUPHAR review 1Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The receptor review details VIP/PACAP signaling and physiology; target mechanisms do not establish clinical efficacy across the discussed diseases.
Reported population / model
Review
Reported study details
Comprehensive analysis of VPAC1/VPAC2/PAC1 receptors
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
11IV Aviptadil in critical COVID-19 respiratory failure: 60-day RCTPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The source reports higher 60-day survival odds in one COVID trial; endpoint hierarchy and later trials must be considered before claiming efficacy.
Reported population / model
Humans
Reported study details
196 patients · IV infusion · 60 days · 2-fold increased survival odds
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
12VIP corrects CIRS acquired following water-damaged building exposurePep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The source attributes broad CIRS improvements to nasal VIP; controlled design and attribution of later imaging/molecular claims need verification.
Reported population / model
Humans
Reported study details
CIRS patients · Nasal spray 50mcg · Multiple months · Correction of inflammatory markers
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
13VIP prevents experimental arthritis by reducing autoimmune and inflammatory componentsPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: A mouse arthritis model reportedly showed less joint inflammation and structural damage after VIP exposure.
Reported population / model
Mice
Reported study details
CIA model · IP injection · 2 weeks · Complete prevention of joint destruction
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
14VIP as a new drug for primary pulmonary hypertensionLinked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography; findings and bibliographic accuracy have not been independently verified.
Pep-Pedia bibliography · Checked 2026-10-12
15From VIP through ADNP to NAP: neuroprotection and cell divisionLinked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography; findings and bibliographic accuracy have not been independently verified.
Pep-Pedia bibliography · Checked 2026-10-12
16Pep-Pedia: VIP — reported pharmacokineticsReference estimate; not independently verified human PKCommunity source checked
AI-PREPARED SUMMARY
Lists a half-life of 30 min and a peak time of 15 min. Stated attribution: Youssef et al. 2022. This value is reported by a secondary reference. The stated attribution has not been independently verified as a route- and formulation-matched human PK measurement. Five half-lives is not complete clearance, and the source’s “cleared” value is not used as a measured endpoint.
Secondary reference page checked; the underlying quantitative claim is not independently confirmed. · Checked 2026-10-12
17Pep-Pedia: VIP — route-specific referenceReference page checked; underlying claims require separate verification.Community source checked
AI-PREPARED SUMMARY
Source page checked across available routes. Protocols, cycles, storage, mechanisms and pairing claims are secondary reports; checking the page does not independently validate those claims. Original concise summaries are used here.
Content coverage audit · Checked 2026-10-12
18TESICO randomized IV aviptadil trialPrimary source checked
AI-PREPARED SUMMARY
Aviptadil did not significantly improve recovery or mortality through day 90 in COVID hypoxemic respiratory failure; hypotension, flushing and diarrhea were more common. Findings concern monitored IV therapy, not nasal CIRS use.
TESICO randomized IV aviptadil trial
Aviptadil did not significantly improve recovery or mortality through day 90 in COVID hypoxemic respiratory failure; hypotension, flushing and diarrhea were more common. Findings concern monitored IV therapy, not nasal CIRS use.
Additional primary-source check · Checked 2026-10-12